Catheter Precision, Inc. (VTAK) - Q3 2025 10-Q Summary
Business Context and Reporting Period
This summary covers the quarterly period ended September 30, 2025. Catheter Precision, Inc. is a medical technology company focused on cardiac electrophysiology (EP). Its primary commercial products are the VIVO System (non-invasive 3D cardiac mapping) and LockeT (suture retention device). The company recently formed two subsidiaries: Cardionomix (acquiring the CPNS System for heart failure treatment) and KardioNav (developing EP mapping technologies). The company executed a 1-for-19 reverse stock split effective August 15, 2025.
Key Financial Metrics
| Metric | Q3 2025 (3 Months) | Q3 2024 (3 Months) | YTD 2025 (9 Months) | YTD 2024 (9 Months) |
|---|---|---|---|---|
| Revenue | $226,000 | $96,000 | $581,000 | $271,000 |
| Gross Profit | $208,000 | $86,000 | $538,000 | $240,000 |
| Gross Margin | 92.0% | 89.6% | 92.6% | 88.6% |
| Operating Loss | $(3,021,000) | $(2,859,000) | $(11,282,000) | $(8,192,000) |
| Net Loss (Attributable to CP) | $(2,251,000) | $(4,120,000) | $(11,405,000) | $(11,015,000) |
| Cash & Equivalents (End of Period) | $1,075,000 | $1,268,000 | $1,075,000 | $1,268,000 |
| Working Capital | $(2,858,000) | $(1,062,000) | $(2,858,000) | $(1,062,000) |
| Accumulated Deficit | $(303,757,000) | $(286,724,000) | $(303,757,000) | $(286,724,000) |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 135% in Q3 2025 compared to Q3 2024, driven primarily by a $92,000 increase in LockeT sales. YTD revenue increased 114%.
- Operating Expenses: SG&A expenses remained relatively flat quarter-over-quarter ($2.95M vs $2.88M) but increased YTD due to higher headcount and professional fees. R&D expenses increased significantly ($276k vs $63k in Q3) due to new development activities at KardioNav.
- Acquired IPR&D: The company recorded $1.97M in acquired in-process research and development expenses YTD 2025, primarily from the Cardionomic asset acquisition (CPNS System) and Perikard acquisition. There was no such expense in the prior year.
- Non-Cash Fair Value Adjustments: The company recorded a $726,000 gain from the change in fair value of royalties payable due to related parties in Q3 2025, compared to a $1.23M loss in Q3 2024. This volatility is driven by changes in projected sales and discount rates.
- Liquidity: Cash decreased from $2.87M at year-end 2024 to $1.08M at Q3 2025. The company has a working capital deficit of $2.86M.
Guidance, Outlook, Risks, and Unusual Items
- Going Concern: Management has concluded there is substantial doubt about the company's ability to continue as a going concern for 12 months from the filing date. Cash on hand is estimated to be insufficient to fund operations through the end of Q4 2025 without additional financing.
- Financing Activities: The company raised $1.5M cash and received $0.86M in trading debt securities (QHSLab Notes) via a May 2025 PIPE financing. Additionally, $4.0M in gross proceeds were raised via an At-The-Market (ATM) offering through September 30, 2025.
- Debt Obligations: Significant related-party debt exists, including notes totaling approximately $1.7M due to related parties (maturity Jan 2026) and $1.3M in notes payable from the Cardionomix acquisition (maturity 2028).
- Internal Controls: The company identified material weaknesses in internal controls over financial reporting, specifically regarding segregation of duties, review controls, and tax provision calculations. A remediation plan is in place.
- Strategic Shifts: Management is exploring "innovative and specialty finance strategies," including a potential crypto asset treasury policy, to secure capital.
Investor Verification Checklist
- Liquidity Runway: Verify the sufficiency of current cash ($1.1M) against the stated need to fund operations through Q4 2025 and the timeline for securing additional capital.
- Related Party Transactions: Review the terms of the $1.7M in related-party notes and the royalty agreements (11.82% on LockeT sales) which significantly impact net income via fair value adjustments.
- Revenue Concentration: Note that 4 customers accounted for 62% of Q3 2025 revenue; verify the stability of these contracts.
- Asset Acquisition Valuation: Assess the commercial viability of the CPNS System (acquired for $1.9M expense) and the Perikard patent, given the company's cash constraints.
- Internal Control Remediation: Monitor progress on fixing material weaknesses in financial reporting to ensure future data reliability.